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Nowadays, applications (apps) for smartphones and tablets have become indispensable 
especially for young generations. The estimated number of mobile devices will exceed 
2.16 billion in 2016. Over 2.2 million apps are available in the Google Play store®, and 
about 1.8 million apps are available in the Apple App Store®. Google and Apple dis-
tribute nearly 70,000 apps each in the category Health and Fitness, and about 33,000 
and 46,000 each in medical apps. It seems like the willingness to use mHealth apps 
is high and the intention to share data for health research is existing. This leads to one 
conclusion: the time for app-accompanied clinical trials (smartRCTs) has come. In this 
perspective article, we would like to point out the stones put in the way while trying to 
implement apps in clinical research. Further, we try to offer a glimpse of what the future 
of smartRCT research may hold.
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iNtrODUctiON
In the twenty-first century, digitalization in day-to-day life is ubiquitous, and besides conventional 
computers, laptops, and mobile phones, the use of smartphones is continuously increasing and 
far beyond writing messages or phone calls. Applications (apps) for smartphones and tablets have 
become indispensable, especially for young generations; however, increasing use of apps in the 
middle-aged and elderly population is observed, thus arguing for a common use across generation 
borders (1). The estimated number of mobile devices will exceed 2.16 billion in 2016 (2). Over 2.2 
million apps are available in the Google Play store®, and about 1.8 million apps are available in the 
Apple App Store®. Google and Apple distribute nearly 70,000 apps each in the category Health and 
Fitness, and about 33,000 and 46,000 each in medical apps (3, 4). The WHO defines these tools under 
the label “mHealth” or “eHealth” as “medical and public health practice supported by mobile devices, 
such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless 
devices” (5). The willingness to use mHealth apps or devices seems high. In a current study, Chen 
et al. (6) showed a great acceptance (77%) to share data for health research, which leads to the natural 
conclusion: the time for app-accompanied clinical trials has come. In addition, we are living in the 
era of Big Data, where lots of data are generated and analyzing strategies need to be found. Big Data is 
defined as “high volume, high velocity, and/or high variety information assets that require new forms 
of processing to enable enhanced decision making, insight discovery, and process optimization.” (7)
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Currently, the medical field shows an evolving trend in 
developing apps used as tools for behavior change therapy or 
lifestyle intervention, such as diabetes, weight loss, or exercise 
performance (8–10). But to date, only a few researchers like 
Volkova et  al. (11) use mobile apps as supporting tools in tri-
als. In their research, they launched the app-based Food Label 
Trial investigating the impact of labels on consumer behavior. 
They created the very apt term “smartRCTs” (app-accompanied 
randomized controlled trials).
In this perspective article, we would like to investigate the 
rocky path while attempting to implement apps in clinical 
research. Further, we try to offer a glimpse of what the future of 
smartRCT research may hold.
LiMitAtiONs AND BArriers  
OF smartrcts
Legal Limitations—Do researchers  
Need a Law Degree?
When implementing apps in clinical research, one of the highest 
barriers to overcome is the legal limitations. The requirements 
differ in each country. We describe the situation in Germany, as it 
has one of the strictest data privacy regulations [place 7 in Privacy 
and Human Rights Report 2007 (12)], and we are experienced 
with the legal situation. Clinical trials need to be approved by 
the ethics committee (preventing unethical practice) and the 
data protection officer (enforcing data privacy laws). Usually, the 
ethics commission supports smartRCTs, if all the data privacy 
regulations are met (13). However, it is difficult to meet the 
requirements of the data privacy officer. Informal consent by 
patients must be obtained before entering the trial. This means, 
besides the usual trial information, patients have to be educated 
about the app technology, secure data transfer (anonymous or 
pseudonymous), data storage, time of storage, and the possibil-
ity to delete data if they discontinue the study. When recruiting 
patients prospectively during treatment this is less problematic, 
but gaining patient consent by phone or letter is difficult and time 
consuming.
The type of data transfer needs to be chosen carefully: 
anonymous data transfer (no patient-related data are trans-
ferred) will not conflict with data privacy regulations. Whereas 
pseudonymous data transfer (patient data are tagged with 
a pseudonym) requires proper planning. Pseudonyms must 
be generated to be untraceable and securely stored. The best 
approach is to set up two different servers: on server A, patients’ 
data are stored, while server B contains the pseudonym and 
identifier. Both servers are not connected, hence, only author-
ized trial personal, who has access to both servers, is able to 
retrieve sensitive data (14).
Further, it is important to be in full control of patient data, 
as the right to informational self-determination is fundamental. 
Data deletion based on patient’s wish needs to be possible. 
However, services from third-party providers often store data 
on remote servers outside the respective law system. Complete 
deletion of data is impossible and, therefore, such services do not 
comply with the law. Furthermore, secure data storage must be 
ensured for at least 10 years, which might lead to data overload 
(described below). It is important to stay—already in the phase of 
trial planning—in close contact with the ethics commission and 
the data privacy officer to meet all regulations and adapt the study 
protocol, if necessary. It would be beneficial if the German data 
privacy regulations and laws would get adjusted to the new tech-
nology to reduce bureaucracy and allow for high-tech research.
Medical apps demand a different quality standard. It is 
crucial that apps in smartRCTs need to meet standardized 
criteria, as they are involved in patient care. In Germany, apps 
that are considered as medical products need to comply with the 
Medizinproduktegesetz (Law for Medical Products) and thus 
must meet stricter criteria as common apps. Medical products 
need clinical testing and certification. Further, compliance 
with the Telemedizingesetz (Law for Telemedicine) needs to 
be ensured. The U.S. Food and Drug Administration published 
similar guidelines (15). Hence, it is viable to ensure the legal status 
of the app before starting the programming phase.
Patients—An App a Day Keeps  
the Doctor Away?
Limitations of smartRCTs are set by the patients themselves. In 
earlier publications, we investigated the attitude toward apps for 
therapeutic and scientific purposes. We saw a dependency on age 
and gender. Men and participants <60 years are more likely to 
use an app (16). The reluctance of female patients needs to be 
further evaluated. The age appears to be a limiting factor in app 
use. In 2014, only 18% of elderly people (>65 years) owned smart-
phones or tablets. Seventy-seven percent of the elderlies would 
request help when learning to use this new technology (17). 
Consequentially, this may lead to a lack of compliance when using 
apps in smartRCTs. In contrast, Smith et al. (18) showed a grow-
ing trend in smartphone use by people >65 years in 2015: already 
27% in the U.S. owned smartphones, which means older citizens 
increasingly adapt to the new technology. Either way, smartRCTs 
must be planned considering involved patient cohort. Trials with 
elderly participants need careful selection of the mobile tools and 
possibly intense pretrial participant teaching. After all, Denis 
et al. showed that patient using mHeatlh apps feel closer to their 
treating doctor due to better communication (19).
Another problem could be that patients do not always own 
an adequate mobile device. Although in industrial countries 
like Germany (60%) or the United States (72%) a majority of 
the citizens is in possession of a mobile device (20), the variety 
of devices and operating systems is huge. Certainly, participa-
tion in smartRCTs can be predicated by adding smartphone 
possession (maybe even with certain operating systems) to the 
inclusion criteria, but this leads to preselection and therefore to 
biased results. One approach is to hand out a mobile device with 
a specified operating system to the participants while taking 
part in the trial. This reduces the costs for developing apps for 
different operating systems and ensures non-biased samples, 
however, requires funding to purchase devices. In summary, 
patients might be a limiting factor when launching a smartRCT, 
but proper preparation and careful planning can lead to an 
exceptional trial compliance.
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staff—An important cog in the Wheel?
As in the case with patients, the age of clinicians and principal 
investigators is an obstacle when implementing smartRCTs. In an 
earlier series, we investigated the attitude of health-care profes-
sionals toward app use of patients during treatment and aftercare. 
The idea of implementing apps was supported by 84.3%; 64.8% 
even preferred to be alerted if patients enter severe side effects, 
which require action. The majority (93.5%) supports scientific 
evaluation of the collected data. The named arguments against 
app use were legal uncertainty regarding medical responsibility; 
wish for sole personal contact between health-care professionals 
and patient; missing technical skills; and lack of time (14).
Legal uncertainty should be minimal within smartRCTs, as 
the study protocol describes precise treatment algorithms, which 
are audited by the ethics commission. Principal investigators and 
staff need to be technically trained. Without proper skills, they 
are not able to work with the used tools, as well as teach patients. 
Certainly, the fear of additional work exists. However, Denis et al. 
(19) showed that treating doctors needed less than 15 min per 
week for data analysis and phone calls within the entire cohort 
of 42 patients. With the appropriate development of automated 
data analyses, the staffs’ work time can be minimized. Time-
consuming clinical visits might be reduced, as some are replaced 
by app-based follow-ups. The delegation of tasks to specifically 
trained medical support staff like study nurses could reduce high 
workloads for principal investigators.
As always when introducing new technologies, there are 
supporters and critics within the medical profession. However, 
a smartRCT can only be successful if all principal investigators 
and the participating staff are technically educated and ready to 
support the project. Otherwise, failure is unavoidable.
technical realization—Let Us start 
Programming in the Garage?
When overcoming all barriers, technical realization of smartRCTs 
is a minor obstacle. Programming from scratch needs qualified 
staff, which increases the costs of trials. Projects with apps require 
also medical computer scientists who not only provide technical 
skills but also understand how medical trials are conducted and 
have basal knowledge of the physicians’ daily work and patients’ 
needs. However, there are open source development kits offered 
by providers (e.g., Apple Researchkit® and Google Study kit®) 
to compose an app based on the respective operating system. 
For instance, Bot et  al. (21) use the Apple Researchkit® in his 
“mPower” Parkinson trial.
As stated above, it is important to match the legal requirements 
for data transfer, security, and privacy when developing apps. Data 
transfer to a cloud or server needs to be encrypted to ensure the 
best possible protection of highly sensitive patient information. 
He et al. (22) showed that few Android mHealth apps match these 
criteria, although technical capabilities are already established: 
Thilakanathan et al. (23) developed a secure protocol for sharing 
patient data in clouds, and Silva et al. (24) presented the DE4MHA 
algorithm for secure encryption. Moreover, data storage needs to 
be encrypted to protect patient data from unauthorized access. 
A long-term storage on secure servers in favor of transparency 
and plausibility of trial data is needed. This may lead to higher 
costs and data overload. Today, public health studies need already 
data storage capacity of 10 trillion bytes (10 TB) and more. This 
would equal tens of millions of floppy disks (25). Eventually, this 
is a future challenge for data transfer, storage, and management 
systems, which is no insurmountable problem.
FUtUre PersPective OF smartrcts
Apps supporting clinical trials—time is 
Money
Besides all the barriers, smartRCTs hold numerous benefits in 
supporting trials. Khan et  al. (26) observed the work time of 
three individual clinical trial managers and showed that tasks 
such as documentation (24%), administrative work (20%), and 
recruitment (16%) are time consuming. Moreover, activities, 
such as filling out case report forms (12%), data entry (10%), 
and recruiting eligible patients (9%), are exhausting. The most 
commonly used tool was paper (24%). Data collection with apps 
can reduce all those tasks and thus duration. Neuer et al. (27) sug-
gest a 30% decrease in duration by using electronic data capture. 
Therefore, data analyses can be achieved faster, and results are 
quicker implemented into clinical routine (28).
The whole process of documentation could be simplified 
by asking patients to document trial parameters, quality of 
life scores, or other information via an app. Consequentially, a 
new dimension of information is added to the usual trial data: 
the patients’ view. Going even a step further, mHealth devices 
such as activity trackers, blood pressure monitors, blood glucose 
meters, or personal scales can be connected with apps. Hence, the 
completeness and timeliness of the data are increased, because 
the course of the disease is monitored longitudinally and not only 
cross-sectional as it is the case with classical periodical visits. 
Highly compliant patients could even enter blood test or imaging 
results made by other physicians (see Figure 1).
Needless to say, it is possible to develop apps to be used two 
sided, and physicians or study nurses could also enter data into the 
app. Standardized entry is guaranteed, and paperwork is dimin-
ished. Reduced paperwork protects the environment and leads 
to a more secure archiving of patient data. Subsequent changes 
of data are more difficult; hence, data transparency is improved. 
Errors during processing and digitizing data are prevented. 
Dependencies can be used to check entries for plausibility, and 
automated algorithms can verify inputs already before storing.
The time-consuming recruitment process can be simplified 
by using apps. It is difficult to find eligible patients for trials 
using the traditional form of recruitment. With mHealth tools, 
a wide range of people can be approached, and, therefore, it is 
easier, faster, and more cost-effective. Laws et al. (29) showed that 
online recruitment compared to a practitioner and face-to-face 
recruitment is the quickest and cheapest form with average costs 
of AUD$ 14 per participant.
With all named benefits a higher cost-effectiveness can be 
achieved. Sertkaya et  al. (30) applied a media data study and 
showed total costs of $78.6 million for phase 1–4 trials inves-
tigating drugs in oncology. Administrative staff costs (phase 3: 
FiGUre 1 | Data collection by mobile applications for smartrcts.
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20.40%), physician costs (phase 3: 7.08%), source data verifica-
tion costs (phase 3: 3.52%), patient recruitment costs (phase 3: 
2.71%), and data management costs (phase 3: 0.34%) (30) can 
be reduced by using app technology where appropriate. The 
prerequisite is that apps operate as safe and without patient dis-
comfort as humans. Sertkaya et al. suggest a total cost reduction 
of 7.91% (=$6.2 million) if mobile technology is used. Eisenstein 
et al. (31) calculated a reduction of 9.8% by using electronic data 
capture.
A huge problem within trials is the inevitable subjectivity of 
research personnel. Various studies of Hróbjartsson et al. (32–34) 
showed an occurring bias, especially if blinding is not feasible. 
App-based data collection is objective as well as standardized, for 
example, pre-validated questionnaires can be used. Furthermore, 
smartRCTs simplify multicenter trials as data transfer is easier and 
all investigators are closely connected. It is possible to centralize 
the data storage and prevent data loss (28). Moreover, app-based 
study procedures are equal and objective within all centers.
The mentioned advantages can be of great scientific value in 
radiation oncology as it is a highly technical discipline. In contrast 
to classical clinical visits, apps can be used for trial documenta-
tion of side effects caused by radiotherapy or concomitant radio-
chemotherapy. Trial compliance is enhanced as apps can be used 
to remind patients of radiation dates or drug intake. Continuous 
aftercare over years plays an important role in radiation oncology. 
App-based research could enhance documentation and therefore 
simplify trials on long-term toxicity. The implementation of 
smartRTCTs would be of great benefit as it marks the departure 
into the new era of radiation oncology 4.0 (35).
Apps and Big Data—i Have a Dream …
smartRCTs and app-based research generate a huge amount of 
data—Big Data. Only a fraction of collected trial data are used 
and published. The data could, however, be utilized to perform 
sub-studies or can be merged to acquire new insights for clini-
cal day-to-day life. Epidemiological researchers could identify 
patterns, causes, and effects of diseases without high costs and 
workload. In return, it is important to improve the level of techni-
cal skills within epidemiological studies (36).
Moreover, Big Data can be used to perform clinical trials 
in silico, which means computer simulations are run instead of 
classical studies (37). Less animal testing and patient recruit-
ment in pharmaceutical or other trials would be needed (38). 
Especially, research in the area of highly rare conditions would 
benefit. Instead of using the hard road of recruiting a huge 
number of patients to gather valid results, computer simulation 
can accompany trials in rare tumor or diseases. Furthermore, 
Big Data shows potential in the evolving genomics research. A 
variety of recently published studies used electronic health data 
to show relationships between genetic variations and clinical 
conditions (39–41). Bowton et al. (42) showed this approach to 
be cost-effective and quick. The Omics movement led to further 
research disciplines: pharmacogenomics investigates effects of 
genetics on the individuals’ drug response. Omics can be used to 
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predict disease probability, a great tool for preventive medicine 
(43). Hence, Big Data and Omics will be a major step toward 
personalized and precise medicine.
cONcLUsiON
smartRCTs and app-based studies are the future of medical 
research—radiation oncology in particular. While there are cer-
tain barriers—especially the data privacy laws—the advantages 
outweigh the limitations. It would be desirable if politicians 
and lawmakers establish better opportunities and adjust the 
regulations to the new technology. This is possible without 
undermining the right to informational self-determination and 
data privacy. Further, all parties involved—data privacy officers, 
ethical commission, patients, and researchers—need to support 
an aspired smartRCT. Necessarily, apps for research need to meet 
certain criteria concerning patient safety and good clinical prac-
tice; therefore, generally accepted standards for trial apps need to 
be established. If so, apps can reduce trial costs, study duration, 
and subjectivity bias as well as collect a wider range of data. One 
thing is clear: smartRCT is not a question of whether or not, but 
of when and how.
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